Somewhat Favorable Press Coverage Somewhat Likely to Affect Calithera Biosciences (CALA) Share Price

Media coverage about Calithera Biosciences (NASDAQ:CALA) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 50.4510026905893 out of 100, indicating that recent news coverage is somewhat likely to have an effect on the company’s share price in the next several days.

A number of equities analysts have commented on the stock. ValuEngine downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 8th. Zacks Investment Research downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Calithera Biosciences presently has an average rating of “Hold” and a consensus target price of $16.50.

Calithera Biosciences stock traded up $0.15 during trading hours on Monday, reaching $4.90. The stock had a trading volume of 6,089 shares, compared to its average volume of 408,484. The company has a market capitalization of $170.94 million, a PE ratio of -5.83 and a beta of 2.38. Calithera Biosciences has a 52 week low of $4.05 and a 52 week high of $18.35.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.23. The business had revenue of $17.07 million during the quarter, compared to the consensus estimate of $5.17 million. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%. equities research analysts predict that Calithera Biosciences will post -1.27 EPS for the current year.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: NASDAQ

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply